<html>

<head>
   <meta http-equiv="Content-Language" content="en-us">
   <meta name="GENERATOR" content="Microsoft FrontPage 5.0">
   <meta name="ProgId" content="FrontPage.Editor.Document">
   <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
   <title>Metabolic Syndrome</title>
   <style>
      p.MsoNormal {
         mso-style-parent: "";
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText {
         margin-bottom: .0001pt;
         line-height: 150%;
         font-size: 14.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText2 {
         margin-bottom: .0001pt;
         text-align: justify;
         line-height: 150%;
         layout-grid-mode: char;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.Index {
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }
   </style>
</head>

<body>

   <p class="MsoNormal" align="center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Metabolic Syndrome</font>
            </span></u></b></p>
   <p class="MsoNormal" align="center" style="text-align: center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Topic Highlights</font>
            </span></u></b></p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Metabolic syndrome is defined as a clustering of major cardiovascular risk factors
            along with abdominal obesity.
         </font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b><br></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">Risk factors include high blood pressure, obesity, low HDL cholesterol, raised triglycerides,
            high cholesterol, and glucose intolerance.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">The root cause of metabolic syndrome is thought to be insulin resistance.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">This presentation provides information on metabolic syndrome and its constituent conditions -
            diabetes, insulin resistance, hypertension and dyslipidemia, with a note on the risk factors and management
            of the condition.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="line-height: 150%;" align="center">
      <b><u><span style="line-height: 150%; font-family: Arial;">
               <font size="4">
                  Transcript</font>
            </span></u></b>
   </p>
   <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
         <span style="line-height: 150%; font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Metabolic_syndrome "
               style="color: blue; text-decoration: underline; text-underline: single">Metabolic syndrome</a> defines a
            clustering of major <a href="https://en.m.wikipedia.org/wiki/cardiovascular"
               style="color: blue; text-decoration: underline; text-underline: single">cardiovascular</a> risk factors,
            in association with (central)<a href="https://en.m.wikipedia.org/wiki/obesity"
               style="color: blue; text-decoration: underline; text-underline: single">obesity</a> and excess weight,
            which includes at least two of the following four risk factors i.e.; raised
            <a href="https://en.m.wikipedia.org/wiki/blood_pressure"
               style="color: blue; text-decoration: underline; text-underline: single">blood pressure</a>, low <a
               href="https://en.m.wikipedia.org/wiki/High-density_lipoprotein"
               style="color: blue; text-decoration: underline; text-underline: single">
               HDL cholesterol</a>, raised <a href="https://en.m.wikipedia.org/wiki/ triglycerides"
               style="color: blue; text-decoration: underline; text-underline: single">triglycerides</a> and <a
               href="https://en.m.wikipedia.org/wiki/glucose_intolerance"
               style="color: blue; text-decoration: underline; text-underline: single">glucose intolerance</a>
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Millions of people have metabolic syndrome. It affects approximately 20% of adults in developed
            countries and 80% of people with <a href="https://en.m.wikipedia.org/wiki/Type_2_diabetes"
               style="color: blue; text-decoration: underline; text-underline: single">type 2 diabetes</a>. While the
            syndrome itself may not affect quality of life, if left unchecked, it is associated with increased risk of
            type 2 diabetes by 9 to 30 times and heart disease by two to four times. It is very strongly linked with
            central obesity and the worldwide rise in obesity is predicted to lead to a rise in the number of people
            with metabolic syndrome. It can affect about 5% of those with normal weight; 22% of those who are overweight
            and nearly 60% of the obese. The risk of developing metabolic syndrome increases by up to 45% in those who
            continue to gain five pounds or more weight per year.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The root cause of the metabolic syndrome is thought to be <a
               href="https://en.m.wikipedia.org/wiki/insulin_resistance"
               style="color: blue; text-decoration: underline; text-underline: single">insulin resistance</a>. Obesity
            and abdominal obesity in particular, lead to insulin resistance, that starts a process that includes
            accelerated <a href="https://en.m.wikipedia.org/wiki/atherogenesis"
               style="color: blue; text-decoration: underline; text-underline: single">atherogenesis</a> and often
            culminates in diabetes, <a href="https://en.m.wikipedia.org/wiki/heart"
               style="color: blue; text-decoration: underline; text-underline: single">heart</a> and <a
               href="https://en.m.wikipedia.org/wiki/vascular_disease"
               style="color: blue; text-decoration: underline; text-underline: single">vascular diseases</a> and <a
               href="https://en.m.wikipedia.org/wiki/stroke"
               style="color: blue; text-decoration: underline; text-underline: single">stroke</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Metabolic syndrome was first described by Reaven and colleagues in 1988 as a link between
            insulin resistance and <a href="https://en.m.wikipedia.org/wiki/hypertension"
               style="color: blue; text-decoration: underline; text-underline: single">hypertension</a>, type 2
            diabetes, <a href="https://en.m.wikipedia.org/wiki/dyslipidemia"
               style="color: blue; text-decoration: underline; text-underline: single">dyslipidemia</a> and other
            metabolic abnormalities that increased an individual's risk of developing <a
               href="https://en.m.wikipedia.org/wiki/atherosclerotic"
               style="color: blue; text-decoration: underline; text-underline: single">atherosclerotic cardiovascular
               diseases</a>. The components of metabolic syndrome include obesity with an increase in waist measurement;
            hypertension; dyslipidemia and <a href="https://en.m.wikipedia.org/wiki/glucose_intolerance"
               style="color: blue; text-decoration: underline; text-underline: single">glucose intolerance</a>.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Other components may include <a href="https://en.m.wikipedia.org/wiki/microalbuminuria"
               style="color: blue; text-decoration: underline; text-underline: single">microalbuminuria</a>; evidence of
            a prothrombotic state with elevated blood <a href="https://en.m.wikipedia.org/wiki/fibrinogen"
               style="color: blue; text-decoration: underline; text-underline: single">fibrinogen</a> and <a
               href="https://en.m.wikipedia.org/wiki/plasminogen_activator_inhibitor'1"
               style="color: blue; text-decoration: underline; text-underline: single">plasminogen activator
               inhibitor'1</a>
            level; and increased inflammatory markers such as raised blood <a
               href="https://en.m.wikipedia.org/wiki/C-reactive_protein"
               style="color: blue; text-decoration: underline; text-underline: single">CRP</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">There are several definitions of metabolic syndrome as defined by a variety of international
            bodies. However, the ones most often referred to are the definitions and guidelines framed by the <a
               href="https://en.m.wikipedia.org/wiki/World_Health_Organization"
               style="color: blue; text-decoration: underline; text-underline: single">World Health Organization</a>
            (WHO), the National Cholesterol Education Project Adult Treatment Panel (NCEP-ATP III); and the <a
               href="https://en.m.wikipedia.org/wiki/International_Diabetes_Federation"
               style="color: blue; text-decoration: underline; text-underline: single">International Diabetes
               Federation</a>(IDF). </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">According to these definitions, the numerical values assigned to the constituent conditions of
            metabolic syndrome are:</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Hypertension: Patients who are currently on antihypertensive medications; or those whose <a
               href="https://en.m.wikipedia.org/wiki/systolic_blood_pressure"
               style="color: blue; text-decoration: underline; text-underline: single">systolic blood pressure</a> is
            greater than 130 mmHg or those whose diastolic blood pressure is greater than 85 mmHg.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Dyslipidaemia"
               style="color: blue; text-decoration: underline; text-underline: single">Dyslipidaemia</a>: Patients who
            have blood triglyceride levels higher than 1.7mmol/L or 150 mg/dL and/or patients whose blood HDL levels are
            less than 0.9mmol/L or 35 mg/dL if males and 1.0mmol/L or 40mg/dL if female.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Obesity: Patients with a <a href="https://en.m.wikipedia.org/wiki/Body_mass_index"
               style="color: blue; text-decoration: underline; text-underline: single">BMI</a> of more than 30 kg/m2
            and/or whose waist circumference is more than 40 inches, if male and more than 35 inches, if female; or
            whose waist to hip ratio is more than 0.9, if male and more than 0.85, if female. Waist circumference less
            than or equal 94cm for Europid men and less than or equal 80cm for Europid women is defined as central
            obesity. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Glucose"
               style="color: blue; text-decoration: underline; text-underline: single">Glucose</a>: Patients with Type 2
            diabetes or with impaired glucose tolerance; or patients whose fasting blood glucose is in excess of
            5.6mmol/L or 100mg/ dL.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Microalbuminuria"
               style="color: blue; text-decoration: underline; text-underline: single">Microalbuminuria</a>: Patients
            with overnight urinary albumin excretion rate of more than 20 mcg/min or 30 mg/g Cr.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">According to the WHO definition, for a confirmed diagnosis of metabolic syndrome, the patient
            should have Type 2 diabetes or impaired glucose tolerance plus any two of the other constituent conditions.
            If glucose tolerance is normal then the patient needs to exhibit at least three of the other constituent
            conditions.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">According to the NCEP-ATP III, having any three out of the five conditions (expanded waist,
            raised triglyerides, low HDL cholesterol, raised blood pressure and glucose intolerance), leads to a
            diagnosis of metabolic syndrome.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">According to the IDF, patients with central obesity and any two of the other four conditions
            qualify for a diagnosis of metabolic syndrome.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The major risk factors for developing metabolic syndrome are obesity and abdominal or central
            obesity combined with a sedentary lifestyle. There are also likely to be genetic susceptibility factors and
            other environmental factors which include smoking, alcohol consumption, <a
               href="https://en.m.wikipedia.org/wiki/menopause"
               style="color: blue; text-decoration: underline; text-underline: single">menopause</a>, high <a
               href="https://en.m.wikipedia.org/wiki/carbohydrate"
               style="color: blue; text-decoration: underline; text-underline: single">carbohydrate</a> diet, age and
            ethnicity.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Metabolic syndrome shows a highly age-dependent prevalence. It's less common below 30 years and
            more common in middle age and beyond; however, the incidence of metabolic syndrome in children and
            adolescents is on the rise due to the increasing incidence of overweight and obese children. The prevalence
            of metabolic syndrome in certain population groups is particularly high. These include South Asians where
            there is associated evidence of increased rates of abdominal/central obesity and in Mexican and Black
            Americans. Low birth weight has been linked to increased risk of obesity and diabetes in adulthood and
            consequently to increased risk of metabolic syndrome.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin is a hormone produced by the beta cells of the <a
               href="https://en.m.wikipedia.org/wiki/pancreas"
               style="color: blue; text-decoration: underline; text-underline: single">pancreas</a> and released into
            the bloodstream where it's taken to the various tissues within the body where it produces its biologic
            effects. It plays an important role in the metabolism of carbohydrate, <a
               href="https://en.m.wikipedia.org/wiki/lipids"
               style="color: blue; text-decoration: underline; text-underline: single">lipids</a>
            and <a href="https://en.m.wikipedia.org/wiki/proteins"
               style="color: blue; text-decoration: underline; text-underline: single">proteins</a>, and helps regulate
            cell growth. Insulin resistance is a condition in which the normal quantities of insulin fail to produce the
            required biologic effects. This means that in a person with type 2 diabetes and insulin resistance, many
            units of insulin per day may be required to produce <a
               href="https://en.m.wikipedia.org/wiki/glycemic_control"
               style="color: blue; text-decoration: underline; text-underline: single">glycemic control</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin produces its biologic effects by binding to insulin receptors and <a
               href="https://en.m.wikipedia.org/wiki/insulin-like_growth_factor_1"
               style="color: blue; text-decoration: underline; text-underline: single">insulin-like growth factor 1</a>
            (IGF-1) receptors present on cell surfaces of target tissues like <a
               href="https://en.m.wikipedia.org/wiki/skeletal_muscle"
               style="color: blue; text-decoration: underline; text-underline: single">skeletal muscle</a>, <a
               href="https://en.m.wikipedia.org/wiki/liver"
               style="color: blue; text-decoration: underline; text-underline: single">liver</a>, <a
               href="https://en.m.wikipedia.org/wiki/kidneys"
               style="color: blue; text-decoration: underline; text-underline: single">kidneys</a> and <a
               href="https://en.m.wikipedia.org/wiki/adipose_tissue"
               style="color: blue; text-decoration: underline; text-underline: single">adipose tissue</a>. The insulin
            receptor is a heterotetrimeric molecule that has two beta chains, which extend extracellularly and two '
            chains that are present across the cell membrane. These chains are linked by <a
               href="https://en.m.wikipedia.org/wiki/disulfide"
               style="color: blue; text-decoration: underline; text-underline: single">disulfide</a> bonds. The <a
               href="https://en.m.wikipedia.org/wiki/cytosolic"
               style="color: blue; text-decoration: underline; text-underline: single">cytosolic</a> end of each ' chain
            carries <a href="https://en.m.wikipedia.org/wiki/tyrosine_kinase"
               style="color: blue; text-decoration: underline; text-underline: single">tyrosine kinase</a> activity.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">When an insulin molecule binds to the trough created by the two alpha chains, the insulin
            receptors undergo a conformational change such that the two ' chains come closer to each other and cause
            transphosphorylation of their tyrosine residues. This autophosphorylated insulin receptor kinase gets
            rapidly absorbed into <a href="https://en.m.wikipedia.org/wiki/endosomes"
               style="color: blue; text-decoration: underline; text-underline: single">endosomes</a>. The endosomal
            system then regulates insulin-signaling pathways. Postreceptor signaling pathways within the target cells
            bring about the action of insulin. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">While many factors can affect the concentration of insulin receptors and the affinity of insulin
            for its receptors, insulin resistance usually results from defects in the target cells, <a
               href="https://en.m.wikipedia.org/wiki/autoantibodies"
               style="color: blue; text-decoration: underline; text-underline: single">autoantibodies</a> to insulin and
            accelerated insulin degradation. The pathophysiology of insulin resistance is based at two levels: the
            effect that insulin has on the metabolic pathways in the body and the cellular mechanisms involved in
            insulin utilization.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Abdominal obesity is strongly associated with insulin resistance. Central or abdominal fat is
            more metabolically active than peripheral fat. The rates of fat storage and fat release are greater in
            central fat deposits than in peripheral fat collections. The link between central obesity and insulin
            resistance arises from a combination of increased production of chemicals (<a
               href="https://en.m.wikipedia.org/wiki/adipokines"
               style="color: blue; text-decoration: underline; text-underline: single">adipokines</a>) produced from fat
            cells ' these include increased <a href="https://en.m.wikipedia.org/wiki/leptin"
               style="color: blue; text-decoration: underline; text-underline: single">leptin</a> and <a
               href="https://en.m.wikipedia.org/wiki/Tumor_necrosis_factor-alpha"
               style="color: blue; text-decoration: underline; text-underline: single">TNF-alpha</a> and reduced <a
               href="https://en.m.wikipedia.org/wiki/adiponectin"
               style="color: blue; text-decoration: underline; text-underline: single">adiponectin</a>. This imbalance
            leads to increased atherogenesis. In addition, excessive free fatty acids are transported to the liver due
            to a higher rate of <a href="https://en.m.wikipedia.org/wiki/lipolysis"
               style="color: blue; text-decoration: underline; text-underline: single">lipolysis</a> in abdominal <a
               href="https://en.m.wikipedia.org/wiki/adipocytes"
               style="color: blue; text-decoration: underline; text-underline: single">adipocytes</a>. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin resistance develops due to the reduced peripheral insulin sensitivity caused by
            adipokine imbalance and the free fatty acid induced reduction in peripheral insulin sensitivity and
            reduction in hepatic insulin uptake, degradation and sensitivity. There is also an increase in the
            production of the enzyme <a
               href="https://en.m.wikipedia.org/wiki/11%CE%B2-hydroxysteroid_dehydrogenase_type_1"
               style="color: blue; text-decoration: underline; text-underline: single">11-beta-hydroxysteroid
               dehydrogenase type-1</a> in individuals with excessive abdominal fat. This enzyme converts inactive
            cortisone to active <a href="https://en.m.wikipedia.org/wiki/cortisol"
               style="color: blue; text-decoration: underline; text-underline: single">cortisol</a>, which encourages
            visceral fatty deposits and insulin resistance.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Most insulin resistance is manifested at a cellular level and away from the point where insulin
            interacts with its receptors. Intracellular signaling pathways that lead to insulin action are most
            significant in development of insulin resistance.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The two major pathways activated by insulin binding to its receptor are the <a
               href="https://en.m.wikipedia.org/wiki/phosphatidylinositol_3-kinase"
               style="color: blue; text-decoration: underline; text-underline: single">phosphatidylinositol-3'-kinase</a>
            or PI3K pathway and the mitogenic or mitogen-activated protein or <a
               href="https://en.m.wikipedia.org/wiki/MAPK/ERK_pathway"
               style="color: blue; text-decoration: underline; text-underline: single">MAP kinase pathway</a>. The
            clinical manifestations of insulin resistance will depend on which one of the postreceptor signaling
            pathways has been disrupted because while the PI3K pathway is important for bringing about the metabolic
            effects of insulin, cell growth and proliferation and procoagulant effects are associated with the MAP
            kinase pathway.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">It has been confirmed in several prospective epidemiological studies across a variety of
            population groups that insulin resistance is an important precursor in the development of Type 2 diabetes.
            Type 2 diabetes begins with peripheral insulin resistance and travels across a continuum of worsening
            insulin action and may end up with a partial failure of the insulin secretory process. For most patients,
            development of type 2 diabetes results from a combination of insulin resistance and impaired pancreatic
            beta-cell secretory capacity with progressive deterioration of beta-cell function over time.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin regulates muscle glucose uptake and limits liver production of glucose by <a
               href="https://en.m.wikipedia.org/wiki/gluconeogenesis"
               style="color: blue; text-decoration: underline; text-underline: single">gluconeogenesis</a>. By limiting
            gluconeogenesis in the liver, and encouraging cellular uptake of glucose in skeletal muscle cells insulin
            controls the amount of glucose in blood. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin resistance can occur at three main sites: the liver, muscle and adipocytes. Peripheral
            insulin resistance involves defects in the postreceptor signaling pathways that prevent glucose uptake by
            the muscle cells. This type of peripheral insulin resistance can occur in persons of normal body weight as
            well as the obese. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">In persons with visceral adiposity, the adipocytes are resistant to the antilipolytic effect of
            insulin and hence release excessive amounts of free fatty acids which find their way to the liver through
            the portal circulation. These free fatty acids in the liver increase gluconeogenesis and result in increased
            blood glucose. Increased gluconeogenesis combined with low peripheral glucose uptake results in high blood
            glucose levels, also known as <a href="https://en.m.wikipedia.org/wiki/hyperglycemia"
               style="color: blue; text-decoration: underline; text-underline: single">hyperglycemia</a>. Hyperglycemia
            signals the pancreas to produce more insulin. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Besides this, high levels of circulating free fatty acids slow down the breakdown of insulin in
            the liver and further contribute to high blood insulin levels. Thus <a
               href="https://en.m.wikipedia.org/wiki/hyperinsulinemia"
               style="color: blue; text-decoration: underline; text-underline: single">hyperinsulinemia</a> occurs along
            with hyperglycemia. This excessive basal glucose production in presence of fasting hyperinsulinemia is a
            characteristic early feature of type 2 diabetes, but progresses over time to reduced insulin secretion.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Dyslipidemia and hypertension are often found in individuals with insulin resistance. The
            compensatory <a href="https://en.m.wikipedia.org/wiki/hyperinsulinemia"
               style="color: blue; text-decoration: underline; text-underline: single">hyperinsulinemia</a> seen in
            insulin resistant individuals leads to an increase in the synthesis of <a
               href="https://en.m.wikipedia.org/wiki/very_low_density_lipoprotein"
               style="color: blue; text-decoration: underline; text-underline: single">very low-density lipoprotein</a>
            or VLDL in the liver. VLDL is converted into triglycerides and <a href="https://en.m.wikipedia.org/wiki/LDL"
               style="color: blue; text-decoration: underline; text-underline: single">LDL</a> and is released into the
            circulation. In peripheral tissues, insulin resistance results in the inability of insulin to act on <a
               href="https://en.m.wikipedia.org/wiki/lipoprotein_lipase"
               style="color: blue; text-decoration: underline; text-underline: single">lipoprotein lipase</a>, which is
            instrumental in the breakdown of triglycerides and LDL in tissues. These effects lead to elevation in plasma
            triglycerides and LDL cholesterol levels. Insulin resistance also results in enhanced rate of synthesis of
            HDL; however, it seems to increase the rate of <a href="https://en.m.wikipedia.org/wiki/apolipoprotein"
               style="color: blue; text-decoration: underline; text-underline: single">apolipoprotein</a> A1/HDL
            cholesterol degradation even more, such that plasma HDL levels reduce.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">There is much clinical evidence that insulin resistance, specifically a disruption of the
            insulin-mediated glucose uptake, and the consequent hyperinsulinemia are common in hypertensive patients,
            although not all hypertensive patients are insulin resistant. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin resistant individuals are more likely to develop hypertension than those who are insulin
            sensitive. Further, the fact that insulin resistance often precedes the development of essential
            hypertension has been proven in several prospective studies.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin resistance results in disruption of the complex genetic, physiological and biochemical
            control systems that help maintain cardiovascular homeostasis and hence a predisposition to hypertension.
            Insulin resistance causes chronic sodium retention and sodium sensitivity in the kidneys and increases
            excretion of water. Insulin resistance enhances the activity of the sympathetic nervous system and
            stimulates growth of the vascular smooth muscle. All these changes contribute to elevating blood pressure.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Apart from dyslipidemia and hypertension, insulin resistance puts into motion a number of other
            mechanisms that lead to arthrogenesis and consequent atherosclerotic events. Insulin resistance results in a
            chronic inflammatory state that is evidenced by increased <a
               href="https://en.m.wikipedia.org/wiki/C-reactive_protein"
               style="color: blue; text-decoration: underline; text-underline: single">C-reactive protein</a> (CRP) in
            blood, which leads to a reduction in <a href="https://en.m.wikipedia.org/wiki/nitric_oxide"
               style="color: blue; text-decoration: underline; text-underline: single">nitric oxide</a> levels. Nitric
            Oxide or NO is essential for maintaining the vascular tone of blood vessel walls and it plays an important
            role in dilating blood vessels and preventing damage to the <a
               href="https://en.m.wikipedia.org/wiki/endothelium"
               style="color: blue; text-decoration: underline; text-underline: single">endothelium</a> during increased
            blood pressure or flow. Increased TNF- alpha levels in the blood of individuals with central adiposity
            increases the ability of LDL cholesterol to bind to blood vessel walls, which is the first step toward the
            formation of atherosclerotic plaques. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Abdominal adipocytes also secrete an adipocytokine that promotes <a
               href="https://en.m.wikipedia.org/wiki/thrombosis"
               style="color: blue; text-decoration: underline; text-underline: single">thrombosis</a>, called <a
               href="https://en.m.wikipedia.org/wiki/Plasminogen_activator_inhibitor-1"
               style="color: blue; text-decoration: underline; text-underline: single">plasminogen activator
               inhibitor-1</a> or PAI-1. PAI-1 inhibits normal <a href="https://en.m.wikipedia.org/wiki/fibrinolysis"
               style="color: blue; text-decoration: underline; text-underline: single">fibrinolysis</a> and elevated
            plasma PAI-1 levels lead to formation of new clots or augmentation of existing clots. In addition to these
            effects, visceral adipocytes produce less <a href="https://en.m.wikipedia.org/wiki/adiponectin"
               style="color: blue; text-decoration: underline; text-underline: single">adiponectin</a> which is a
            protective protein secreted by subcutaneous adipocytes. Hence insulin resistant and viscerally obese
            individuals are deprived of the protective effects of adiponectin, which include increasing insulin
            sensitivity, protection of vascular endothelium and reduction in circulating free fatty acids as well as
            increased clearance of triglycerides.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">
            Dyslipidemia or high plasma triglycerides and low HDL levels, elevated blood pressure and damage to the
            vascular endothelium begin the process of arthrogenesis that culminate in atherosclerotic diseases in
            individuals with insulin resistance.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Patients with metabolic syndrome have an increased risk of cardiovascular events and mortality
            so the main aim of management is to reduce that risk. This has led to a focus on lifestyle measures
            including attention to diet, reduction of weight, increased physical activity and not smoking. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Initially the pharmacotherapeutic focus was on single risk factor intervention but this has now
            been replaced by multiple risk factor intervention using combinations of <a
               href="https://en.m.wikipedia.org/wiki/antihypertensives"
               style="color: blue; text-decoration: underline; text-underline: single">antihypertensives</a>, low dose
            <a href="https://en.m.wikipedia.org/wiki/aspirin"
               style="color: blue; text-decoration: underline; text-underline: single">aspirin</a> (once blood pressure
            has been controlled), <a href="https://en.m.wikipedia.org/wiki/statins"
               style="color: blue; text-decoration: underline; text-underline: single">statins</a> and <a
               href="https://en.m.wikipedia.org/wiki/antihyperglycemic"
               style="color: blue; text-decoration: underline; text-underline: single">antihyperglycemic</a> agents (in
            cases with diabetes). There has also been interest in more directly targeting the underlying insulin
            resistance through both lifestyle intervention and the use of drugs such as <a
               href="https://en.m.wikipedia.org/wiki/rimonabant"
               style="color: blue; text-decoration: underline; text-underline: single">rimonabant</a>, the first <a
               href="https://en.m.wikipedia.org/wiki/cannabinoid_receptor"
               style="color: blue; text-decoration: underline; text-underline: single">endocannabinoid-1 receptor</a>
            blocker. The latter has a central appetite suppressant effect but also peripheral effects including effects
            on fat at least partially correcting adipokine imbalance, with improvements in HDL, triglycerides and
            glycemic control. This drug is presently the subject of long term trials of cardiovascular risk reduction
            and there is no doubt other drugs specifically targeting insulin resistance will be developed in the future.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">For the present, lifestyle and multiple cardiovascular risk factor intervention remain the most
            important aspects of management of this increasingly prevalent condition.</font>
      </span>
   </p><br><br>

   <center>
      <div id="google_translate_element"></div>
   </center>
   

   

<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>